XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Net Revenue $ 9,670,778 $ 6,277,133 $ 17,482,001 $ 11,286,569
Cost of goods sold 958,086 536,405 1,763,167 1,010,838
Gross profit 8,712,692 5,740,728 15,718,834 10,275,731
Operating expenses        
Selling, general and administrative expenses 10,428,133 6,562,144 19,803,763 11,971,874
Research and development 1,067,000 103,981 1,271,637 222,193
Depreciation and amortization 412,028 100,807 614,775 191,398
Total operating expenses 11,907,161 6,766,932 21,690,175 12,385,465
Operating loss (3,194,469) (1,026,204) (5,971,341) (2,109,734)
Other expense        
Interest and accretion expense (63,427) (63,427) (711)
Share of losses from equity method investment (179,769) (379,633) (278,904)
Total other expense (63,427) (179,769) (443,060) (279,615)
Net loss (3,257,896) (1,205,973) (6,414,401) (2,389,349)
Less: Net loss attributable to noncontrolling interest (12,512) (34,481) (39,693) (36,113)
Net loss attributable to Sanara MedTech shareholders $ (3,245,384) $ (1,171,492) $ (6,374,708) $ (2,353,236)
Net loss per share of common stock, basic and diluted $ (0.42) $ (0.16) $ (0.83) $ (0.33)
Weighted average number of common shares outstanding, basic and diluted 7,791,431 7,496,604 7,699,422 7,158,503